Peptide injection sites — what published protocols specify.

Almost everything written about peptide injection sites is somebody describing their own routine. There is a documented version of this subject, and it is narrower and more interesting: the sites named in trial protocols and approved-drug labels, and the absorption data that explains why those documents bother to name them at all.

The reason a Phase III protocol names its injection site is that the site is a variable. Change it and you can change the absorption curve, which changes the exposure the trial is actually measuring. So the site gets written down, fixed, and rotated on a schedule — the same way a diluent or a storage temperature gets written down.

That makes the published record genuinely informative here, and it makes almost everything else on the topic guesswork. What follows is the documented part, with the sources attached.

Which sites do published peptide protocols use?

For subcutaneous delivery, three. The Mounjaro prescribing information specifies subcutaneous injection into the abdomen, thigh or upper arm, with sites rotated at each dose. The Zepbound label carries the same three. So does the broader incretin literature that the peptide research market takes its reference points from.

• Abdomen. The most-used site in the trial record, avoiding the immediate periumbilical area. Large surface area, consistent subcutaneous depth in most adults, easy to sub-divide into a rotation grid.
• Thigh. The anterior and lateral thigh. Second-most common, and the site where subcutaneous depth varies most between individuals.
• Upper arm. The posterior aspect. Named in the labels and used in trials, though it is the hardest of the three for a person to reach on themselves, which is why clinical protocols using it usually involve a second person.

The tirzepatide labels state that exposure is comparable across the three sites. That is a useful and often-misread finding: it means the label treats them as interchangeable for the approved product at approved doses, not that site is irrelevant in general. Insulin, delivered at much smaller volumes and on a much tighter time course, shows the opposite — site-to-site differences that matter clinically.

Does the injection site change absorption?

Yes, and by how much depends on the molecule. Two things vary between sites: local blood flow, and the depth and composition of the subcutaneous layer above the muscle.

For rapid-acting insulin, the difference is large enough that injection technique guidance treats site as a clinical variable. The FITTER recommendations, drawn up by 183 diabetes specialists from 54 countries and published in Mayo Clinic Proceedings, are built around exactly this: needle length, depth, and site consistency, because getting any of them wrong moves the absorption curve.

For the long-acting acylated peptides — the tirzepatide and semaglutide class — the picture flattens out. An albumin-binding acyl chain creates a slow-release depot that dominates the absorption profile, so local perfusion differences get absorbed into a curve measured in days rather than minutes. That is why their labels can call the three sites comparable.

The practical reading for anyone working from published data: the site is part of the protocol, and a result generated at one site is evidence about that site. The general principle is the same one that governs route selection — the evidence attaches to the conditions it was generated under.

BPC-157

Tissue Repair

Pentadecapeptide 15 aa RUO labeled

A representative lyophilized research vial. Lab-verified identity, third-party COA matched to the lot, U.S. domestic fulfillment.

Shop BPC-157

Why do protocols rotate injection sites?

Because not rotating produces lipohypertrophy, and lipohypertrophy corrupts the data before it corrupts anything else.

Lipohypertrophy is a thickening of subcutaneous fat at a repeatedly used site. Blanco and colleagues examined the injection sites of 430 insulin-injecting outpatients and found it in 64.4% of them. The association with technique was not subtle. Of the patients who rotated sites correctly, 5% had lipohypertrophy. Of the patients who had it, 98% either did not rotate or rotated incorrectly.

The consequence is absorption that no longer matches the protocol. In the same cohort, 49.1% of patients with lipohypertrophy showed glycaemic variability, against 6.5% of those without it. Unexplained hypoglycaemia followed the same split. Delivering an accurately measured quantity into thickened tissue produces an inaccurate exposure, and nothing upstream of the site can compensate for that.

Where do intramuscular protocols place the injection?

Different sites, chosen against different constraints. Clinical protocols name the deltoid, the vastus lateralis of the thigh, and the ventrogluteal region, and they name specific anatomical landmarks within each because the surrounding nerve and vascular structures leave a narrow margin.

That is the substantive difference between the two routes at site level. Subcutaneous site selection is about absorption consistency. Intramuscular site selection is about anatomy, and getting it wrong has consequences that have nothing to do with pharmacokinetics. It is a clinical procedure performed by trained personnel, and the published protocols that use it are staffed accordingly.

Intramuscular delivery is uncommon in the peptide literature anyway, for the reason set out in the route comparison: most peptide therapeutics are engineered for a slow subcutaneous depot, and faster absorption defeats the chemistry.

How much volume does one site take?

Published subcutaneous limits sit around 1–1.5 mL per site for adult abdomen and slightly less for thigh and upper arm. Above that, swelling and altered absorption kinetics set in, which is why protocols needing more volume split the delivery across sites.

This runs straight back into the reconstitution step, and it is the part most people get backwards. The diluent volume chosen at reconstitution fixes the concentration, and the concentration fixes how much liquid a given quantity occupies. A 10 mg vial in 2 mL gives 5 mg/mL, so 1 mg is 0.2 mL. The same vial in 10 mL gives 1 mg/mL, and the same 1 mg is now a full millilitre — at the per-site ceiling before anything else has gone wrong.

The peptide calculator works that chain in both directions: vial mass and diluent volume to concentration, then concentration to draw volume in U-100 syringe units. It is worth running before the diluent goes in rather than after.

Bacteriostatic Water

Reconstitution Diluent

0.9% benzyl alcohol Multi-dose vial 28-day in-use window

Sterile water with 0.9% benzyl alcohol — the diluent that sets the concentration every volume figure on this page depends on. One bottle reconstitutes several vials.

Learn more

Do any of these site rules apply to research-use-only material?

Not as instructions, no. This is the point the rest of the page is built around, so it is worth stating without hedging.

Research-use-only peptides are sold under 21 CFR § 809.10(b)(9) and carry the label “For Research Use Only. Not for human or veterinary use.” That statement is a regulatory category, not a formality: it is the seller declaring the limit of what was sold. The sites above come from approved-drug labels and clinical trial protocols, where an approval and a research ethics framework exist. Neither transfers to a research reagent, and we set out why on the legal position page.

• What this page is for. Reading the published record accurately — understanding why a protocol names a site, and what a result generated at that site is evidence of.
• What it is not for. Supplying a procedure. There is no site on this page that we are telling anyone to use, because the material this site covers has no human-use pathway.
• What does transfer. The bench-side handling. Aseptic vial technique and correct storage are laboratory practice, and they apply to a reagent regardless of what is ever done with it.